• Medicare Will Not Fully Cover Aduhelm, the Controversial-and Costly-Alzheimer's Disease Drug

    5 days ago - By Time

    Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer's drug whose benefits have been widely questioned , a major development in the nation's tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.
    The initial determination from the Centers for Medicare and Medicaid Services means that patients taking Biogen's Aduhelm medication will have to be part of research efforts to assess the drug's effectiveness in slowing the progression of dementia. Medicare's national coverage determination would become final...
    Read more ...